TriangleChimeric Antigen Receptor T-Cell… (NCT06815029)
Chimeric Antigen Receptor T-Cell Therapy trial for Recurrent Glioblastoma (NCT06815029). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Glioblastoma almost always returns after surgery, radiation, and chemotherapy; at recurrence, nothing reliably extends life.
The idea: deliver engineered immune cells straight into the brain, and delete the switch the tumor uses to shut them down.
City of Hope has treated glioblastoma with CAR T cells aimed at IL13Rα2, a marker on most of these tumors, infused through a small catheter into the brain. Glioblastoma pours out TGF-beta, which quiets immune cells. Here, the gene for the TGF-beta receptor is knocked out of the T cells first, so the tumor's brake no longer works on them. Doses are given weekly for four weeks, then more if tolerated.
Behnam Badie leads the trial in Duarte. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.